The emerging communication architecture in electrical energy supply and its implications

In the course of liberalisation of the electrical energy market, the pressure on the utilities to reduce their investment and maintenance costs is increasing. In order to lower these expenses and to be able to offer a more efficient supply with electrical energy, the utilities are increasingly using modern communication techniques. Control mechanisms that have been realized with a huge amount of hardware so far are more and more replaced by softwarebased solutions. Major points of concern in the near future are the standardisation of communication interfaces and protocols, as well as the implementation of autonomously acting entities performing vitally important actions like controlling protective systems

Full scale rotor blade deformation measurements in comparison with aeroelastic simulations based on measured high-resolution wind fields

Aeroelasticity is one of the biggest challenges in wind turbine rotor design, as the length of rotor blades increases which comes along with a slenderer design. The knowledge of the aeroelastic turbine behavior is of great importance. A comparison to field measurements is of huge importance when validating aeroelastic tools. However, the measurement of deformation and torsion in the field is not trivial and the conduction of realistic post-test simulations is a challenge. One crucial factor for these simulations is the wind field, which needs to be captured in a high spatial and temporal resolution. In this paper, the results of deformation measurements conducted in the field with an optical measurement method called Digital Image Correlation (DIC) on one rotor blade will be shown and compared to aeroelastic post-test simulations using highly resolved wind fields measured with a SpinnerLidar. © 2020 Published under licence by IOP Publishing Ltd

Elara: A Phase 2 Trial Investigating The Efficacy And Safety Of Tisagenlecleucel In Adult Patients With Refractory/Relapsed Follicular Lymphoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149492/1/hon6_2632.pd

Cyber-physical energy systems modeling, test specification, and co-simulation based testing

The gradual deployment of intelligent and coordinated devices in the electrical power system needs careful investigation of the interactions between the various domains involved. Especially due to the coupling between ICT and power systems a holistic approach for testing and validating is required. Taking existing (quasi-) standardised smart grid system and test specification methods as a starting point, we are developing a holistic testing and validation approach that allows a very flexible way of assessing the system level aspects by various types of experiments (including virtual, real, and mixed lab settings). This paper describes the formal holistic test case specification method and applies it to a particular co-simulation experimental setup. The various building blocks of such a simulation (i.e., FMI, mosaik, domain-specific simulation federates) are covered in more detail. The presented method addresses most modeling and specification challenges in cyber-physical energy systems and is extensible for future additions such as uncertainty quantification

An Integrated Research Infrastructure for Validating Cyber-Physical Energy Systems

Renewables are key enablers in the plight to reduce greenhouse gas emissions and cope with anthropogenic global warming. The intermittent nature and limited storage capabilities of renewables culminate in new challenges that power system operators have to deal with in order to regulate power quality and ensure security of supply. At the same time, the increased availability of advanced automation and communication technologies provides new opportunities for the derivation of intelligent solutions to tackle the challenges. Previous work has shown various new methods of operating highly interconnected power grids, and their corresponding components, in a more effective way. As a consequence of these developments, the traditional power system is being transformed into a cyber-physical energy system, a smart grid. Previous and ongoing research have tended to mainly focus on how specific aspects of smart grids can be validated, but until there exists no integrated approach for the analysis and evaluation of complex cyber-physical systems configurations. This paper introduces integrated research infrastructure that provides methods and tools for validating smart grid systems in a holistic, cyber-physical manner. The corresponding concepts are currently being developed further in the European project ERIGrid.Comment: 8th International Conference on Industrial Applications of Holonic and Multi-Agent Systems (HoloMAS 2017

Long-term research challenges in wind energy – a research agenda by the European Academy of Wind Energy

The European Academy of Wind Energy (eawe), representing universities and institutes with a significant wind energy programme in 14 countries, has discussed the long-term research challenges in wind energy. In contrast to research agendas addressing short- to medium-term research activities, this eawe document takes a longer-term perspective, addressing the scientific knowledge base that is required to develop wind energy beyond the applications of today and tomorrow. In other words, this long-term research agenda is driven by problems and curiosity, addressing basic research and fundamental knowledge in 11 research areas, ranging from physics and design to environmental and societal aspects. Because of the very nature of this initiative, this document does not intend to be permanent or complete. It shows the vision of the experts of the eawe, but other views may be possible. We sincerely hope that it will spur an even more intensive discussion worldwide within the wind energy community

Green and animal manure use in organic field crop systems

Dual-use cover/green manure (CGM) crops and animal manure are used to supply nitrogen (N) and phosphorus (P) to organically grown field crops. A comprehensive review of previous research was conducted to identify how CGM crops and animal manure have been used to meet N and P needs of organic field crops, and to identify knowledge gaps to direct future research efforts. Results indicate that: (a) CGM crops are used to provide N to subsequent cash crops in rotations; (b) CGM-supplied N generally can meet field crop needs in warm, humid regions but is insufficient for organic grain crops grown in cool and sub-humid regions; (c) adoption of conservation tillage practices can create or exacerbate N deficiencies; (d) excess N and P can result where animal manures are accessible if application rates are not carefully managed; and (e) integrating animal grazing into organic field crop systems has potential benefits but is generally not practiced. Work is needed to better understand the mechanisms governing the release of N by CGM crops to subsequent cash crops, and the legacy effects of animal manure applications in cool and sub-humid regions. The benefits and synergies that can occur by combining targeted animal grazing and CGMs on soil N, P, and other nutrients should be investigated. Improved communication and networking among researchers can aid efforts to solve soil fertility challenges faced by organic farmers when growing field crops in North America and elsewhere

Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: The OPTIPARK open-label study

BACKGROUND: The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal trials. METHODS: OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK under clinical practice conditions. Patients with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian treatments. The primary endpoint was the Clinician’s Global Impression of Change (CGI-C) after 3 months. Secondary assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). RESULTS: Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients completed 3 months of treatment. Overall, 71.3 and 76.9% of patients experienced any improvement on CGI-C and PGI-C after 3 months, respectively (full analysis set). At 6 months, for UK subgroup only (n = 95), 85.3% of patients were judged by investigators as improved since commencing treatment. UPDRS scores at 3 months showed statistically significant improvements in activities of daily living during OFF (mean ± SD change from baseline: − 3.0 ± 4.6, p < 0.0001) and motor scores during ON (− 4.6 ± 8.1, p < 0.0001). The mean ± SD improvements of − 3.4 ± 12.8 points for PDQ-8 and -6.8 ± 19.7 points for NMSS were statistically significant versus baseline (both p < 0.0001). Most of TEAEs (94.8% of events) were of mild or moderate intensity. TEAEs considered to be at least possibly related to opicapone were reported for 45.1% of patients, with dyskinesia (11.5%) and dry mouth (6.5%) being the most frequently reported. Serious TEAEs considered at least possibly related to opicapone were reported for 1.4% of patients. CONCLUSIONS: Opicapone 50 mg was effective and generally well-tolerated in PD patients with motor fluctuations treated in clinical practice. TRIAL REGISTRATION: Registered in July 2016 at clinicaltrials.gov (NCT02847442)

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal trials. Methods OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK under clinical practice conditions. Patients with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian treatments. The primary endpoint was the Clinician’s Global Impression of Change (CGI-C) after 3 months. Secondary assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Results Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients completed 3 months of treatment. Overall, 71.3 and 76.9% of patients experienced any improvement on CGI-C and PGI-C after 3 months, respectively (full analysis set). At 6 months, for UK subgroup only (n = 95), 85.3% of patients were judged by investigators as improved since commencing treatment. UPDRS scores at 3 months showed statistically significant improvements in activities of daily living during OFF (mean ± SD change from baseline: − 3.0 ± 4.6, p < 0.0001) and motor scores during ON (− 4.6 ± 8.1, p < 0.0001). The mean ± SD improvements of − 3.4 ± 12.8 points for PDQ-8 and -6.8 ± 19.7 points for NMSS were statistically significant versus baseline (both p < 0.0001). Most of TEAEs (94.8% of events) were of mild or moderate intensity. TEAEs considered to be at least possibly related to opicapone were reported for 45.1% of patients, with dyskinesia (11.5%) and dry mouth (6.5%) being the most frequently reported. Serious TEAEs considered at least possibly related to opicapone were reported for 1.4% of patients. Conclusions Opicapone 50 mg was effective and generally well-tolerated in PD patients with motor fluctuations treated in clinical practice. Trial registration Registered in July 2016 at clinicaltrials.gov (NCT02847442)